Education

This activity focuses on optimizing the management of major depressive disorder (MDD) by addressing residual symptoms and side effects associated with conventional antidepressants. Participants will review the latest data on precision serotonin receptor modulators, their mechanisms of action, and strategies for antidepressant selection and switching to enhance outcomes through shared decision-making and collaborative care.

This activity examines the significant burden of anhedonia in major depressive disorder (MDD), highlighting its impact and the limitations of traditional treatments. Participants will explore the neurobiological underpinnings and emerging precision treatments for anhedonia, while learning to implement patient-centered strategies to assess and optimize its management.

This educational activity explores the use of atypical antipsychotics (AAPs) in treating depressive episodes, focusing on differentiating bipolar depression (BD) from major depressive disorder (MDD) to enhance diagnostic accuracy. Participants will gain insights into the challenges of managing these conditions, review FDA-approved AAPs' mechanisms, efficacy, and safety, and develop strategies for effective treatment implementation.